Product Comparison


 

No Image

Merck 00006412102 Merck 00006483703 Merck 00006404741 Merck 00006409502
McKesson # 1021373 952614 911398 544446 927964
Description PLATE,5.825",HW,125PK,AST Gardasil® 9 Human Papillomavirus 9-Valent Vaccine, Recombinant, Preservative Free 20 mcg - 60 mcg / 0.5 mL Injection 0.5 mL Pneumovax® 23 Pneumococcal 23 Vaccine Polyvalent 25 mcg / 0.5 mL Injection 0.5 mL RotaTeq® Rotavirus Vaccine, Live, Oral Pentavalent Solution 2 mL Vaqta® Pediatric Hepatitis A Virus Vaccine, Preservative Free 25 Unit / 0.5 mL Injection 0.5 mL
Manufacturer # DXE-SXP6WSPK00006412102000064837030000640474100006409502
Brand  Gardasil® 9Pneumovax® 23RotaTeq®Vaqta® Pediatric
Manufacturer ESSENDANT CO/UNITED STATIONERSMerckMerckMerckMerck
Invoice PLATE,5.825",HW,125PK,ASTGARDASIL 9 HPV VACC, SYR 0.5ML(10/BX)PNEUMOVAX, SYR 0.5ML (10/CT)ROTATEQ VAC, SUSP 2ML LIVE PENTAV (10/PK)VAQTA, SYR PED 25U/0.5ML (10/BX)
    Log In to Order   Log In to Order   Log In to Order   Log In to Order   Log In to Order

Comparison

Application Human Papillomavirus Vaccine (HPV)Pneumonia VaccineRotavirus VaccineHepatitis A Vaccine
Container Type Prefilled SyringePrefilled SyringeSingle-Dose TubePrefilled Syringe
Country of Origin UnknownAustriaUnited StatesUnited StatesUnited States
Dosage Form InjectionInjectionSolutionInjection
Generic Drug Code 37568438592650032393
Generic Drug Name Human Papillomavirus 9-Valent Vaccine, Recombinant, Preservative FreePneumococcal 23 Vaccine PolyvalentRotavirus Vaccine, Live, Oral PentavalentHepatitis A Virus Vaccine, Preservative Free
NDC Number 00006412102000064837030000640474100006409502
Product Dating McKesson Acceptable Dating: we will ship >= 180 daysMcKesson Acceptable Dating: we will ship >= 180 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 120 days
Storage Requirements Requires RefrigerationRequires RefrigerationRequires RefrigerationRequires Refrigeration
Strength 20 mcg - 60 mcg / 0.5 mL25 mcg / 0.5 mL25 Unit / 0.5 mL
Type IntramuscularIntramuscular or SubcutaneousOralIntramuscular
UNSPSC Code 51201649512016155120161851201626
User Indicated for People 9 to 45 Years of AgeIndicated for People 50 Years of Age and OlderIndicated for People 6 to 32 Weeks of AgeIndicated for People 12 Months to 18 Years of Age
Volume 0.5 mL0.5 mL2 mL0.5 mL
Features and Benefits
  • GARDASIL 9 is a non-infectious recombinant 9-valent vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
  • Each 0.5-mL dose contains approximately 30 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 60 mcg of HPV Type 16 L1 protein, 40 mcg of HPV Type 18 L1 protein, 20 mcg of HPV Type 31 L1 protein, 20 mcg of HPV Type 33 L1 protein, 20 mcg of HPV Type 45 L1 protein, 20 mcg of HPV Type 52 L1 protein, and 20 mcg of HPV Type 58 L1 protein
  • Administer GARDASIL 9 intramuscularly as a 0.5-mL dose at the following schedule: 0, 2 months, 6 months
  • Not all vulvar, vaginal, and anal cancers are caused by HPV, and GARDASIL 9 protects only against those vulvar, vaginal, and anal cancers caused by HPV 16, 18, 31, 33, 45, 52 and 58
  • PNEUMOVAX 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine
  • PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged >2 years who are at increased risk for pneumococcal disease
  • Box of 10 single-dose, pre-filled Luer-Lok™ syringes with tip caps, color coded with a violet plunger rod and purple stripe on the syringe labels and cartons
  • Store unopened and opened vials at 2° - 8°C (36° - 46°F)
  • The vaccination series consists of three ready-to-use liquid doses of RotaTeq* administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4 to 10 week intervals
  • 10 individually pouched single dose tubes
  • Each dose is supplied in a container consisting of a squeezable plastic dosing tube with a twist-off cap, allowing for direct oral administration
  • VAQTA® [Hepatitis A Vaccine, Inactivated] is indicated for the prevention of disease caused by hepatitis A virus (HAV) in persons 12 months of age and older
  • VAQTA is a sterile suspension for intramuscular injection
  • One milliliter of the vaccine contains approximately 50U of hepatitis A virus antigen, which is purified and formulated without a preservative
  • Each 0.5-mL pediatric dose contains 25U of hepatitis A virus antigen and adsorbed onto approximately 0.225 mg of aluminum provided as amorphous aluminum hydroxy phosphate sulfate, and 35 mcg of sodium borate as a pH stabilizer, in 0.9% sodium chloride